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tionswere based in Asia (k4), North America (k3), Africa (k3) and Europe (k2).
The target population of these publications were the general public (k7), patients
(k4) or both (k1). A slight majority of the 12 primary evidence publications (k7)
and a larger majority of the 5 secondary evidence publications (k4) reported a SP
bias on the results of the BG. Various parameters such as male gender, higher
education and higher income levels were, in some instances, associated with
higherWTP amounts. Other factors analysed are the population surveyed (patients
vs. general population), and the location of the study. Association between these
factors and the occurrence of starting point bias is examined and will be reported.
CONCLUSIONS: There is evidence in the literature of a SP bias on the results of BGs,
without however a full consensus on the matter. Further research is warranted in
order to evaluate the conditions under which such bias appears.
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A LOOK AT PREVIOUS AND CURRENT METHODS USED TO COLLECT PATIENT-
REPORTED OUTCOMES INFORMATION
Bergstrom F1, Bolognese J1, Tran D2
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OBJECTIVES: Patient reported outcomes (PROs) have become an important compo-
nent of many clinical studies. The use of ePRO as a data collection method can
alleviate the potential burden experienced by patients and/or sites. The purpose of
this survey studywas to capture current PROdata collection trends and summarize
these findings side-by-sidewith results fromaprevious PROdata collection survey.
METHODS: Industry professionals were invited to complete a web-based survey
fielded in late 2011 and early 2012. This survey included questions on professional
demographics, experience using PROs (and ePROs) by study type and experience
with ePRO technologies. Responses were analyzed descriptively. RESULTS: To
date, 54 industry professionals completed the 2011-2012 survey. Fifty nine percent
of respondents were from pharmaceutical companies, biotech (26%), medical de-
vice (9%), and other (6%).While 49% of respondents in the 2010 survey had previous
PRO study experience, 60% of respondents in the current survey had previous PRO
experience. The proportion of respondents with prior ePRO experience, however,
was similar across the two surveys (51% in 2010 and 54% in 2011-2012). Hand-held
device (tablet, PDA) was the most common ePRO technology (71% in 2011, 64% in
2010), followed by interactive voice response (47% in 2011, 60% in 2010), and inter-
active web-response (29% in 2011, 51% in 2010). Among those with prior ePRO
exposure in 2011 and 2010, respectively, 59% and 86% strongly agreed/agreed they
would use ePRO in future studies. Among thosewho never used ePROs, 58% in 2011
and 50% in 2010 indicated they would likely use ePROs in future studies.
CONCLUSIONS: Results from this survey suggest that ePRO use continues to gain
moderate acceptance among industry professionals. These findings, however,
were based on a limited sample size. Future surveys should be administered to
allow future trends in ePRO use to be observed over time.
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TRANSLATION AND CULTURAL ADAPTATION OF THE LANGUAGE
DEVELOPMENT SURVEY
Griffin A1, Wild D1, Rescorla L2, Sunderaju R3
1Oxford Outcomes, Oxford, Oxfordshire, UK, 2Bryn Mawr College, Bryn Mawr, PA, USA,
3University of Vermont, Burlington, VA, USA
OBJECTIVES: The Language Development Survey (LDS) assesses children’s word
combinations and vocabulary and provides an accurate picture of a child’s devel-
oping language when completed by a parent or guardian. The LDS contains a list of
310 basic words. The person completing the questionnaire is asked to circle those
words their child says spontaneously. Translations already existed in over ten
languages. Twelve further languages were translated, including eight Indic lan-
guages. A direct translation of some source words was not possible as some items
are unknown in the target country, e.g. pretzel, spaghetti, Sesame St. Therefore, it
was necessary to find a conceptually equivalent source word. METHODS: Two
approaches were adopted: An initial translatability assessment was carried out to
identify problematic words. Equivalent source words were suggested. Further
problematic words were identified during the translation and cognitive-debriefing
process. Alternatives were suggested either during the translation stages or by the
parent/guardian during the cognitive debriefing interview. Final wording was
agreed on through discussion with the lead in-country translator and instrument
developers. RESULTS: A number of cultural adaptations were made. For all Indian
languages, ‘cracker’ was translated as ‘papadom’ (a thin, crisp Indian cracker) and
‘pizza’ as translated as ‘dosa’ (a type of Indian pancake). This was decided before
the initial translation step. ‘Sesame St.’ was replaced with ‘Tom and Jerry’. In
French ‘saucisse’ was suggested as an alternative for ‘hot dog’ during cognitive
debriefing.CONCLUSIONS:When translating a patient-reported outcome (PRO) the
aim is to produce a translation that is conceptually equivalent to the source text. In
some cases, cultural adaptation is essential. Translation of the LDS is an excellent
example of this methodology and the translations are now available for use in
multi-national studies.
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PATIENT PREFERENCES FOR REMINDERS IN CLINICAL TRIALS: IMPROVING
BOTH COMPLIANCE AND PATIENT EXPERIENCE
Ross J, Ross E
Almac Clinical Technologies, Souderton, PA, USA
OBJECTIVES: This session intends to identify patients’ preferences for receiving
reminders when participating in clinical trials. Results of a survey on patient ex-
periences will be reported. Recommendations for developing reminder strategies
will be provided with the intention of enhancing the patient’s experience and
compliance. METHODS: An internet survey was administered to patients (in De-
cember 2010) who participated in at least one clinical trial with patient diaries in
the past two years. The survey focused on patients’ perceived experiences and
preferences with patient diaries/ePRO, and how patient diary methods could be
improved. This session will focus on the questions relating to patient reminders–
specifically relating to preferences for how reminderswere sent/received, activities
for which reminders were found most useful, frequency of reminders, etc.
RESULTS: Reminder methods patients preferred most were email and text mes-
sages. Two areas patients preferred to be reminded about were any action required
of them as part of their clinical trial participation and when they were required to
record an electronic-diary entry. When patients were asked about how often they
wanted to receive reminders, the most frequent responses included whenever
there was new information related to their trial participation and once per day.
Patients also provided suggestions for reminders in future trials. CONCLUSIONS:
The results focus onwhat patients are telling industry what they do/do not want in
terms of reminders; these perspectives should be accounted for to enhance the
patient journey and compliance. If industry implements the reminder strategy
wrong (for instance, annoying patients by reminding them too frequently), that
may actually impact compliance negatively. Remind patients when necessary/not
too often. Remind patients in ways they will be able to best receive/notice them.
Appropriate use of reminders drives compliance and incorporating patient prefer-
ences will not only improve compliances rates, but will also enhance the patient’s
experience.
RESEARCH ON METHODS – Statistical Methods
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OBJECTIVES: Accurately estimating the upper bounds of confidence intervals for
rare events such as hospitalization or death is an important activity in safety stud-
ies and outcomes research. Confidence intervals, however, for rare events are sub-
ject to considerable variation based upon the overall sample size and total number
of observed events. This has led to a challenging convention that a minimum of 2
or 3 events are needed for computing meaningful confidence intervals. The objec-
tive of this study was to quantify the variation of the upper bound of confidence
intervals for a binomial proportion in the setting of rare events. METHODS: Clop-
per-Pearson confidence intervals were constructed for sample sizes ranging from
50 to 1000, and numbers of events from 0 to 5. The robustness of the confidence
interval was evaluated by calculating additional confidence intervals assuming: 1)
one more observed event than in the original sample and, 2) that the proportion of
events is equal to the upper bound of the confidence interval for the original
sample. RESULTS: With sample sizes of 50, 100, 200, 500 and 1000, the upper
bounds of the confidence intervals were 13.71%, 7.04%, 3.57%, 1.44% and 0.72%,
respectively, with 2 observed events in the original sample; 16.55%, 8.52%, 4.32%,
1.74% and 0.87%, respectively, (3 observed events); and, 26.40%, 13.94%, 7.16%,
2.91% and 1.47%, respectively, when the proportion of events was equal to the
upper bound of the confidence interval for the original sample with 2 events. Sim-
ilar trends were seen when using other numbers of observed events.
CONCLUSIONS: The upper bounds of confidence intervals for rare events vary
greatly with sample sizes and the numbers of events observed when the sample
size is small. A minimum of 500 subjects is optimal for constructing confidence
intervals for rare events, even if 2 events or less are observed.
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PSEUDO-RANDOMIZATION IN RETROSPECTIVE ANALYSIS USING THE
GENERALIZED MULTINOMIAL LOGIT FOR PROPENSITY SCORE GENERATION
Wilson SM, Mayne T
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OBJECTIVES:Todevelop and test a three-way propensity scorematching algorithm
to provide pseudo-randomization of subjects into three groups to allow for com-
parable groups in a retrospective study. METHODS: Logistic regression using the
generalized multinomial logit linking function was used to calculate estimates of
the propensity score: the probability of having received three putatively inter-
changeable drugs from demographic (Race, Gender, Age) and comorbidities (Charl-
son Comorbidities Index) in a large, retrospective database. The most costly drug
was used as the reference group, and the probability of each treatment group
having received the reference drug was retained as the propensity score. In the
initial analysis 23,912, 4,789, and 4,318 individualswere available in the three treat-
ment regimens. Random subsets of 1/4 and 1/10 the original sample were con-
structed for the purpose assessing multi-group propensity score matching (PSM)
effectiveness in constructing comparable groups via pseudo-randomization with
varying starting sample sizes. PSM was conducted using calipers ranging from 8
digits to one digit of propensity score. Assessment of among-group differences
before and after PSM were conducted using Chi-square tests for categorical vari-
ables and GLM analysis, with difference scores and their confidence intervals for
continuous variables. RESULTS: For all sample sizes, prior to propensity score
matching, significant differences existed among the three treatment regimens for
all variables: gender, race, age and comorbidities. Following PSM there were 3381
matched triplets in the full sample. There were no significant differences among
groups for gender, age or comorbidities; there were significant but tiny differences
that remained for racial representation. In the smaller samples, 966 and 416
matched triplets were retained. There were no significant differences on any
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variable. CONCLUSIONS: Logistic regression using a generalized multinomial logit
link appears to provide a good propensity score fromwhich pseudo-randomization
into three groups can be performed in a retrospective sample.
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NETWORK META-ANALYSIS OF STUDIES WITH OUTCOMES AT MULTIPLE TIME
POINTS USING FRACTIONAL POLYNOMIALS
Vieira da Silva MC1, Jansen JP2
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OBJECTIVES: Network meta-analysis of randomized controlled trials (RCTs) are
often based on one effect measure per study. However, many studies have data
available at multiple time points. Furthermore, not all studies might have mea-
sured the outcomes at the same time points. As an alternative to network meta-
analysis based on the results at one time point, a networkmeta-analysismethod is
presented that allows for the simultaneous analysis of outcomes at multiple time
points.METHODS: The development of outcomes over time of interventions com-
pared in a RCT are modeled with fractional polynomials, and the difference be-
tween the parameters of these polynomials within a trial are synthesized across
studies with a Bayesian network meta-analysis. RESULTS: The proposed models
are illustrated with an analysis of RCTs evaluating interventions for osteoarthritis
of the knee. Fixed and randomeffects first and second order fractional polynomials
were evaluated. CONCLUSIONS: Network meta-analysis with models where the
treatment effect is represented with several parameters using fractional polyno-
mials can be used to simultaneously analyze results at multiple follow-up times
that are not consistent across studies.
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CONTROLLING FOR MULTIPLICITY IN PURSUIT OF A PRO-BASED LABEL WHEN
MULTIPLE PROS ARE ASSESSED
Cole JC
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OBJECTIVES: The FDA’s final Guidance for industry on patient reported outcome
(PRO) use in support of labeling claims was issued in December, 2009. In their
Guidance, the FDA noted that a study’s endpoint model must consider the hierar-
chy of multiple endpoints, including how PROs used for a label claim fit into this
hierarchy. Whereas most studies implement a basic sequential gatekeeping pro-
cess to articulate their hierarchy, this may place some potential labels at risk.
Researchers should be knowledge of the various ways familywise error is influ-
enced and how best to control for it with an informed multiplicity plan as part of
their endpoint model. METHODS: Outcomes from previously published literature
were examined for the influence of various familywise error issues and related
multiplicity controls, including analytic issues, gatekeeping, and precision alpha
control (vs. Bonferroni or Hochberg). RESULTS: In a study with one clinical and
three PRO outcomes, A Bonferroni correction resulted in just one significant result.
A gatekeep between primary and secondary outcomes resulted in two significant
findings. Finally, when using either an adjustment for known-levels of correlation
to adjust alpha (Tukey’s test of statistical certainty) or using a repeated measures
ANOVA vs. change-score analysis, three of the outcomes were classified as
significant. CONCLUSIONS: Researchers should understand the implications of
theirmultiplicity control in order tomake informed decisions about their analyses,
organization of their endpointmodel, and ultimatelymake the best plans to ensure
their desired PRO-based label claims have the most accurate demonstration of
their statistical probability.
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OBJECTIVES: In Health Economics, the estimation of disease specific attributable
cost is of major importance. For this estimation, cost data of cases (patients with
the disease) and comparable controls (patients without the disease) are often uti-
lized. When individual level data are available, regression and GLM models, ad-
dressing issues such as skeweness and heteroscedasticity, can be applied. When
only aggregate level data (e.g. sample means and standard deviations per strata)
are available, thesemodelsmay not be appropriate.METHODS:Here,motivated by
real pressure ulcer cost data, we propose and study a Bayesian Gamma regression
mixed model that utilizes as stochastic nodes both sample means and inverse
coefficients of variation. We investigate its performance and goodness of fit (using
deviance) using various simulated data and compare it with two linear models,
assuming known and unknown cost variances per stratum. We also use the
method for estimating pressure ulcer attributable costs. RESULTS: In most cases,
the linear models give more accurate estimates of the attributable cost, with sig-
nificantly shorter computational time. The random effects adapt to the multipli-
cative nature of the data, posterior means between intercept and slope are posi-
tively correlated. CONCLUSIONS: When only aggregate data are available, the
simplest linear model seems to estimate the attributable costs sufficiently well.
The proposed Gamma model, despite being more theoretically justifiable, is of
questionable benefit. Further investigation is needed for refining the Gamma
model and selecting appropriate measures of model assessment and comparison.
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DIAGNOSTIC TOOLS FOR THE ASSESSMENT OF THE UNDERLYING MODEL
ASSUMPTIONS IN THE STUDY OF HEALTH CARE COSTS
Juneau P
Thomson Reuters, Boyds, MD, USA
OBJECTIVES: It is a common practice to use a log link and assume a gamma distri-
bution when performing regressions of health care costs as an outcome on a set of
potential predictors. In many circumstances, this approach is reasonable and per-
forms well; however, do circumstances exist where these assumed model charac-
teristics are untenable? If so, do simple diagnostic procedures exist that can assess
the appropriateness of model assumptions for regressionmodels involving cost as
an outcome? METHODS: Application of residual analyses available in common
statistical software packages (e.g., SAS) afford practitioners the ability to graphi-
cally and analytically evaluatewhether the choice of a link is appropriate in a given
cost model regression scenario. These same tools can also assist with an assess-
ment of overall model fit. RESULTS: The author will juxtapose contrasting cases of
where the choice of a generalized linear model with a log link and an assumed
gamma distribution are defensible and where these assumptions are not met and
may lead to errors in subsequent inference. CONCLUSIONS:With the use of these
readily available diagnostic procedures found in common software packages it is
possible to easily evaluatewhether underlyingmodel assumptions are tenable and
if the choice of a simpler, more common approach may actually demonstrate
higher fidelity to its underlying model assumptions than the commonly used gen-
eralized linear model with a gamma distribution and a log link.
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HOW TO PRESENT THE PROBABILITY OF BEING THE BEST TREATMENT IN THE
CONTEXT OF A BAYESIAN NETWORK META-ANALYSIS OF PARAMETRIC
SURVIVAL CURVES?
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OBJECTIVES: Increasingly, network meta-analysis (NMA) of published survival
data are based on parametric survival curves as opposed to reported hazard ratios
to avoid relying on the proportional hazards assumption, which may not be valid.
One advantage of a Bayesian approach to NMA is that the probability of being the
best treatment out of all those compared can be calculated. This directly supports
decision-making. However, in the context of survival analysis multiple options are
available.METHODS: Based on a case study in oncology, the probability that each
treatment is best in terms of overall survival was calculated and presented based
on the following underlying RESULTS: 1) the hazard over time, 2) the cumulative
hazard over time, 3) the survival proportions over time, 4) the expected survival
over time, 5) the expected survival at maximum follow-up, 6) expected survival
when all patients have died, and 7) median survival. RESULTS: Since the NMA of
survival curves results in changing hazard and survival estimates over time for the
compared interventions, calculations of the probability that a certain treatment is
best varies with the different alternatives. With methods 1-4 the probability that a
certain treatment is best will vary as a function of follow-up, which provides rele-
vant information. With methods 5-7 only one probability of being the best is ob-
tained for each treatment, which is easier to understand. Method 1 does not di-
rectly relate to the survival proportion, whichmakes it not very intuitive. Method 7
discards a lot of information. CONCLUSIONS: Different approaches to present the
probability of being the most efficacious treatment for findings obtained with a
NMA of survival curves have pros and cons. The probability that a certain treat-
ment is best as a function of survival proportions over time, as well as expected
survival over time seem the most useful and intuitive.
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META-REGRESSION MODELS TO ADDRESS HETEROGENEITY AND
INCONSISTENCY IN NETWORK META-ANALYSIS OF SURVIVAL OUTCOMES
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OBJECTIVES: As an alternative to network meta-analysis (NMA) of survival data
based on the single constant hazard ratio (HR), NMA with a multi-dimensional
treatment effectwere introduced recently.With thesemodels theHR ismodeled as
a function of time, and violations of the transitivity assumption are less likely. Bias
is still present, however, if there are systematic differences in effect modifiers
across comparisons. The objective of this paper is to extend multidimensional
NMA models for survival data with treatment-by-covariate interactions to adjust
for confounding bias.METHODS: By means of an example network of randomized
controlled trials evaluating different interventions for melanoma, three different
approaches for the analysis of overall survival (OS) are compared. 1) NMAassuming
a constant HR between treatment and control group for each study; 2) a two-
dimensional NMA model assuming survival outcomes are described by a Weibull
function; and 3) an extension of method 2 with treatment-by-covariate interac-
tions to adjust for systematic differences across studies. RESULTS: The models
with the two-dimensional treatment effect (approach 2 and 3) fit more closely to
the data than the model with the constant HR (approach 1). Adding treatment-by-
covariate interactions for the scale parameter of the two-dimensional NMAmodels
reduced inconsistency. CONCLUSIONS: Adding treatment-by-covariate interac-
tions to multi-dimensional NMA models for published survival curves is worth-
while to explain systematic differences across studies and reduce inconsistencies.
An additional advantage is that heterogeneity in survival data can be addressed.
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